A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.
The drugmaker revealed the data a year after stopping a Phase III trial.
Phase III clinical trial results underwhelm investors who feel on-market drugs offer better patient value.
The company is rolling out two new clinical trials, and Phase I data suggests an antidote could be on its way.
The calculator meant to help doctors use the new cholesterol guidelines appears to be flawed.
Aggressive new recommendations for treating patients at high risk of cardiovascular disease could significantly alter the treatment landscape.
The drugmaker's latest financial plans could power it through mid-2015.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
The FDA told the drugmaker in a letter before the December PDUFA date that evidence does not support an expanded indication.
An advisory committee voted 9 to 2 against expanding the drug's indication.
Three former workers are accused of giving proprietary data to a drug company abroad.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
The $25 million-plus deal is for worldwide rights to an experimental treatment being developed by private firm Gliknik.
The company has off-loaded two medications and a manufacturing site, part of an ongoing effort.
The scandal over Diovan draws regulatory attention.
Sanofi's PCSK9 agent receives high praise from analysts, Consumer Reports analyzes healthcare reform, Congressional committees propose compounding legislation, NIH funds genomic research.
The advisory panel endorsed the treatment with an 11-2 vote.
FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO
The experimental LAMA/LABA combination could shake up the category.
CDC finds that non-Medicare adults make up the majority of preventable heart attack and stroke cases; a Facebook study shows groups can influence HIV screening; and a Shire ADHD drug gets a "no" from Germany
Researchers say a two-year study shows the DPP-IV drug is not linked to a higher cardiovascular risk.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
Three studies take on different angles of the patient experience. Spoiler alert: no cost increases are mentioned.
Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.
A Data and Safety Monitoring Board recommendation has wiped aleglitazar from the drug maker's slate of possible diabetes medications.
Onyx says no to Amgen bid, yes to other options; Pfizer/BMS may be able to expand Eliquis appeal; Covidien officially divides into two.
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don't protect diabetics' hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients
Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.